Details

Autor(en) / Beteiligte

• Khoury, Paneez
• Makiya, Michelle A.
• Rahim, Rodaba
• Bowman, Abbie
• Espinoza, David
• Schiffenbauer, Adam
• Koch, Megan
• Anderson, Charles
• Constantine, Gregory
• Maric, Irina
• Sun, Xiaoping
• Pittaluga, Stefania
• Brown, Thomas
• Ware, JeanAnne M.
• Wetzler, Lauren
• Fay, Michael P.
• Klion, Amy D.

Titel

Mepolizumab incompletely suppresses clinical flares in a pilot study of episodic angioedema with eosinophilia

Ist Teil von

• Journal of allergy and clinical immunology, 2024-03, Vol.153 (3), p.821-830.e6

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2024

Link zum Volltext

Quelle

Access via ScienceDirect (Elsevier)

Beschreibungen/Notizen

• Episodic angioedema with eosinophilia (EAE) is a rare multilineage cyclic syndrome of unknown etiology characterized by episodes of angioedema, myalgia, fatigue, and fever that occur every 3 to 8 weeks and resolve between episodes without therapy. Cyclic elevations in serum IL-5 levels and neutrophils precede the increase in absolute eosinophil count (AEC) in most patients. We sought to assess the role of IL-5–driven eosinophilia in the clinical manifestations of EAE. An open-label pilot study of mepolizumab (700 mg intravenously monthly for 3 months followed by sequential dose reduction to the Food and Drug Administration–approved dose of 300 mg subcutaneously monthly) was conducted. The primary end point was reduction in the number and severity of clinical symptoms as assessed by patient-reported symptom questionnaires. Secondary end points were greater than or equal to 75% reduction in peak AEC after 1 dose of mepolizumab and sustained reduction in AEC after 3 doses of mepolizumab. Exploratory end points included effects of mepolizumab treatment on other cell lineages (numbers and surface marker expression), levels of plasma mediators, and biomarkers of eosinophil activation. Four female and 1 male (median age, 45 years) participants with EAE were enrolled. None of the 5 participants experienced a reduction in the number of symptomatic flares on mepolizumab therapy, and 1 participant withdrew before study completion because of lack of improvement. Peak AEC was reduced by 75% or more in 3 participants after the first dose of mepolizumab and in 4 participants after 3 doses. In a small cohort of participants with EAE, mepolizumab was unsuccessful in substantially reducing clinical symptoms despite reduction in AEC.